{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:15:05Z","timestamp":1768886105296,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.amjmed.2019.08.013","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T11:27:40Z","timestamp":1567682860000},"page":"182-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6387-1351","authenticated-orcid":false,"given":"Orly","family":"Vardeny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2019.08.013_bib0001","series-title":"National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States","year":"2017"},{"issue":"16","key":"10.1016\/j.amjmed.2019.08.013_bib0002","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"New Engl J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2019.08.013_bib0003","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6 Suppl 1","key":"10.1016\/j.amjmed.2019.08.013_bib0004","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","article-title":"Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.amjmed.2019.08.013_bib0005","doi-asserted-by":"crossref","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","article-title":"Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2","volume":"300","author":"Hummel","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"issue":"22","key":"10.1016\/j.amjmed.2019.08.013_bib0006","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2019.08.013_bib0007","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2019.08.013_bib0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2019.08.013_bib0009","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"10166","key":"10.1016\/j.amjmed.2019.08.013_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.amjmed.2019.08.013_bib0011","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus","volume":"138","author":"Radholm","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.amjmed.2019.08.013_bib0012","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.amjmed.2019.08.013_bib0013","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","article-title":"Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit","volume":"12","author":"Thong","year":"2018","journal-title":"Prim Care Diabetes"},{"issue":"9","key":"10.1016\/j.amjmed.2019.08.013_bib0014","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic Diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.amjmed.2019.08.013_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J Diabetes Investig"},{"issue":"24","key":"10.1016\/j.amjmed.2019.08.013_bib0016","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2019.08.013_bib0017","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1574886309666140120100255","article-title":"Safety of canagliflozin in patients with type 2 diabetes","volume":"9","author":"Mikhail","year":"2014","journal-title":"Curr Drug Saf"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319307065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319307065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:18:32Z","timestamp":1757582312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934319307065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0002934319307065"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.08.013","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}